Rates of Hospitalization for Ulcerative Colitis and Crohn's Disease in Brazil: An Analysis of Socioeconomic Disparities - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Rates of Hospitalization for Ulcerative Colitis and Crohn's Disease in Brazil: An Analysis of Socioeconomic Disparities

  • By

  • Jenny Diniz Malentaqui Lousada

  • Carla Peluso

  • Bianca Bianco

  • Jean Henri Maselli-Schoueri

  • Luiz Vinicius de Alcantara Sousa

  • Fernando Rocha Oliveira

  • Laércio da Silva Paiva

  • February 7, 2026

Share

  • 1

    Inflammatory bowel disease (IBD) includes ulcerative colitis and Crohn's disease, characterized by chronic inflammation of the gastrointestinal tract.

  • 2

    The pathogenesis of IBD involves genetic predisposition, dysregulation of the immune system, and alterations in the intestinal microbiota.

  • 3

    In Brazil, the incidence of IBD is increasing, with significant challenges in obtaining accurate epidemiological data due to lack of mandatory reporting.

  • 4

    This study analyzes hospital admissions for IBD in Brazil from 2010 to 2023, focusing on socioeconomic disparities and their impact on disease occurrence.

  • 5

    Socioeconomic indicators, such as the Social Vulnerability Index and Human Development Index, are crucial for understanding IBD hospitalization trends in Brazil.

Original Source(s)

Rates of Hospitalization for Ulcerative Colitis and Crohn's Disease in Brazil: An Analysis of Socioeconomic Disparities

  • by Jenny Diniz Malentaqui Lousada, Carla Peluso, Bianca Bianco, Jean Henri Maselli-Schoueri, Luiz Vinicius de Alcantara Sousa, Fernando Rocha Oliveira, Laércio da Silva Paiva

  • February 7, 2026

Related Content

Link Between Blastocystis Subtypes 3 and 4 and Intestinal Inflammation as Well as Metronidazole Efficacy in Symptomatic Individuals

3 Innovations Revolutionizing IBD Treatment

Keck Medicine of USC gastroenterologist Florence-Damilola (Damie) Odufalu, MD, shares how recent advances in inflammatory bowel disease treatment are changing the lives of patients.

  • by

  • May 26, 2026

  • 5 min
This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min